Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Phu V. Truong

E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Oxaliplatin-Induced Tonic-Clonic Seizures

Case Reports in Oncological Medicine
Oncology
2015English

Related publications

NCI 8628: A Randomized Phase 2 Study of Ziv-Aflibercept and High-Dose Interleukin 2 or High-Dose Interleukin 2 Alone for Inoperable Stage III or IV Melanoma

Cancer
Cancer ResearchOncology
2018English

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 Mg/Kg Plus Ipilimumab 3 Mg/Kg Expansion Cohort Results

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

A Phase-Ii Study of Combination of Pegylated Interferon Alfa-2a and Capecitabine in Locally Advanced or Metastatic Renal Cell Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

A Phase II Trial of Tremelimumab (CP-675,206) in Patients With Advanced Refractory or Relapsed Melanoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

OA13 High-Dose Icotinib in Advanced NSCLC With EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy